ProfileGDS5678 / 1454031_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 51% 51% 51% 50% 49% 48% 50% 51% 51% 51% 51% 50% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.278751
GSM967853U87-EV human glioblastoma xenograft - Control 23.2266851
GSM967854U87-EV human glioblastoma xenograft - Control 33.2262551
GSM967855U87-EV human glioblastoma xenograft - Control 43.1752951
GSM967856U87-EV human glioblastoma xenograft - Control 53.1635550
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2559449
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2270148
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1957750
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1964551
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2141551
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.211951
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.251
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2199750
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2125951